Cargando…
Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer
BACKGROUND: A considerable number of patients with stage II/III colorectal cancer (CRC) will relapse within 5 years after surgery, which is a leading cause of death in early-stage CRC. The current TNM stage system is limited due to the heterogeneous clinical outcomes displayed in patients of same st...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358813/ https://www.ncbi.nlm.nih.gov/pubmed/34394098 http://dx.doi.org/10.3389/fimmu.2021.702594 |
_version_ | 1783737418336174080 |
---|---|
author | Liu, Zaoqu Lu, Taoyuan Li, Jing Wang, Libo Xu, Kaihao Dang, Qin Liu, Long Guo, Chunguang Jiao, Dechao Sun, Zhenqiang Han, Xinwei |
author_facet | Liu, Zaoqu Lu, Taoyuan Li, Jing Wang, Libo Xu, Kaihao Dang, Qin Liu, Long Guo, Chunguang Jiao, Dechao Sun, Zhenqiang Han, Xinwei |
author_sort | Liu, Zaoqu |
collection | PubMed |
description | BACKGROUND: A considerable number of patients with stage II/III colorectal cancer (CRC) will relapse within 5 years after surgery, which is a leading cause of death in early-stage CRC. The current TNM stage system is limited due to the heterogeneous clinical outcomes displayed in patients of same stage. Therefore, searching for a novel tool to identify patients at high recurrence-risk for improving post-operative individual management is an urgent need. METHODS: Using four independent public cohorts and qRT-PCR data from 66 tissues, we developed and validated a recurrence-associated immune signature (RAIS) based on global immune genes. The clinical and molecular features, tumor immune microenvironment landscape, and immune checkpoints profiles of RAIS were also investigated. RESULTS: In five independent cohorts, this novel scoring system was proven to be an independent recurrent factor and displayed excellent discrimination and calibration in predicting the recurrence-risk at 1~5 years. Further analysis revealed that the high-risk group displayed high mutation rate of TP53, while the low-risk group had more abundance of activated CD4+/CD8+ T cells and high expression of PD-1/PD-L1. CONCLUSIONS: The RAIS model is highly predictive of recurrence in patients with stage II/III CRC, which might serve as a powerful tool to further optimize decision-making in adjuvant chemotherapy and immunotherapy, as well as tailor surveillance protocol for individual patients. |
format | Online Article Text |
id | pubmed-8358813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83588132021-08-13 Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer Liu, Zaoqu Lu, Taoyuan Li, Jing Wang, Libo Xu, Kaihao Dang, Qin Liu, Long Guo, Chunguang Jiao, Dechao Sun, Zhenqiang Han, Xinwei Front Immunol Immunology BACKGROUND: A considerable number of patients with stage II/III colorectal cancer (CRC) will relapse within 5 years after surgery, which is a leading cause of death in early-stage CRC. The current TNM stage system is limited due to the heterogeneous clinical outcomes displayed in patients of same stage. Therefore, searching for a novel tool to identify patients at high recurrence-risk for improving post-operative individual management is an urgent need. METHODS: Using four independent public cohorts and qRT-PCR data from 66 tissues, we developed and validated a recurrence-associated immune signature (RAIS) based on global immune genes. The clinical and molecular features, tumor immune microenvironment landscape, and immune checkpoints profiles of RAIS were also investigated. RESULTS: In five independent cohorts, this novel scoring system was proven to be an independent recurrent factor and displayed excellent discrimination and calibration in predicting the recurrence-risk at 1~5 years. Further analysis revealed that the high-risk group displayed high mutation rate of TP53, while the low-risk group had more abundance of activated CD4+/CD8+ T cells and high expression of PD-1/PD-L1. CONCLUSIONS: The RAIS model is highly predictive of recurrence in patients with stage II/III CRC, which might serve as a powerful tool to further optimize decision-making in adjuvant chemotherapy and immunotherapy, as well as tailor surveillance protocol for individual patients. Frontiers Media S.A. 2021-07-29 /pmc/articles/PMC8358813/ /pubmed/34394098 http://dx.doi.org/10.3389/fimmu.2021.702594 Text en Copyright © 2021 Liu, Lu, Li, Wang, Xu, Dang, Liu, Guo, Jiao, Sun and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Zaoqu Lu, Taoyuan Li, Jing Wang, Libo Xu, Kaihao Dang, Qin Liu, Long Guo, Chunguang Jiao, Dechao Sun, Zhenqiang Han, Xinwei Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer |
title | Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer |
title_full | Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer |
title_fullStr | Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer |
title_full_unstemmed | Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer |
title_short | Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer |
title_sort | clinical significance and inflammatory landscape of anovel recurrence-associated immune signature in stage ii/iii colorectal cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358813/ https://www.ncbi.nlm.nih.gov/pubmed/34394098 http://dx.doi.org/10.3389/fimmu.2021.702594 |
work_keys_str_mv | AT liuzaoqu clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT lutaoyuan clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT lijing clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT wanglibo clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT xukaihao clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT dangqin clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT liulong clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT guochunguang clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT jiaodechao clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT sunzhenqiang clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer AT hanxinwei clinicalsignificanceandinflammatorylandscapeofanovelrecurrenceassociatedimmunesignatureinstageiiiiicolorectalcancer |